Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1136/jitc-2019-000173
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2020
Authors
Publisher
BMJ